Lead chelation therapy retards the decline of renal function in patients with chronic kidney disease
Vecihi Batuman
Correspondence Nephrology Section-SL45, Tulane University Medical Center, 1430 Tulane Avenue, New Orleans, LA 70112-2632, USA
Email vbatuma@tulane.edu
This article has no abstract so we have provided the first paragraph of the full text.
Lead exposure has long been associated with hypertension and kidney disease.1, 2 Although blood lead levels—and presumably BLB—have declined worldwide thanks to the recognition of the health hazards of lead and its removal from gasoline, the association between lead and kidney disease persists.3 This knowledge has, however, had little impact on clinical practice, partly because of lingering doubts about the ability of lead chelation therapy to slow the progression of CKD despite positive results from two studies by Lin-Tan et al.4, 5
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
